High-yielding 3D bioprinter could accelerate drug development, finds research

Industry Insights

Following a research initiative, nanoengineers at the University of California have led to a breakthrough development for 3D printing. The team developed a high-throughput bioprinting technology, when combined with 3D prints can generate a 96-well array of samples of living human tissue in 30 minutes.

In fact, based on clinical knowledge, 3D printer that rapidly produces large batches of customized biological tissue and could help speed up drug development and make it less expnsive.

Going back to the research finding, the ability to generate living human tissue samples rapidly could speed up disease modeling and high-throughput drug screening at preclinical stage.

 Meanwhile, for pharmaceutical companies, the process to develop a new drug can take up to 15 years and cost up to US$ 2.6 billion. For the process, generally, it begins with screening very large number of drug prospect in test tubes. The ones that are successful are then tested in animals, and the ones that pass this stage move for clinical trials. With luck, one of the successfully tested drugs make into commercial market labeled as FDA approved.

Importantly, the 3D bioprinting technology developed by the research team could speed up the initial steps of the process. This would enable drug developers to rapidly build large quantities of  human tissues, for the testing part and to eliminate drug candidates at a much earlier stage.

“Working on human tissue, it enables to obtain better data, better human data on how the drug will work,” stated one of the researchers. To facilitate this, the 3D bioprinting technology can create tissues with high precision, high reproducibility, and high-throughput capability. Resultantly, this could help pharmaceutical companies considerably to find and work on the most promising drugs.

Leave a Reply